Merck KGaA's Erbitux fails in colon cancer study
FRANKFURT (Reuters) - Germany's Merck KGaA said on Wednesday that Erbitux, one of its most important drugs, failed to help colon cancer patients after surgery in a late stage trial.
A scheduled interim analysis of the so-called Petacc-8 study, which tested Erbitux in combination with standard chemotherapy as a treatment of colon cancer that has started spreading, showed no improvement in disease-free survival compared with using chemotherapy only.
Merck's Erbitux competes with Amgen Vectibix in the market for certain colorectal cancer treatments and is also approved for treating head and neck cancer.
(Reporting by Ludwig Burger)
- Tweet this
- Share this
- Digg this
- Tesco accounting black hole deepens, chairman to step down |
- Hungary plans new tax on Internet traffic, public calls for rally
- UKIP on course to win second parliamentary seat - poll
- Some U.S. hospitals weigh withholding care to Ebola patients
- Canada's Harper pledges tougher security laws after attack |